Apellis Pharmaceuticals, Inc. Common Stock
APLSApellis Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing eye and immune system therapies. Founded in 2009, it specializes in complement immunology to create treatments for diseases such as geographic atrophy, paroxysmal nocturnal hemoglobinuria, and other immune-related conditions. The company leverages its innovative complement inhibition platform to address unmet medical needs in both ophthalmology and systemic diseases.
Company News
Markets traded cautiously on Tuesday despite benign inflation data (CPI at 2.7% YoY, core CPI at 2.6%) that supported Fed rate cut expectations. Silver surged 4.5% to $89/oz amid supply concerns. Major indices remained flat with the S&P 500 near record highs. Earnings results were mixed: JPMorgan fell 3% on weak investment banking fees, Delta sli...
Apellis Pharmaceuticals reported preliminary full-year 2025 U.S. net product revenues of $689 million, driven by strong performance from SYFOVRE (geographic atrophy treatment) at $587 million and EMPAVELI (kidney disease treatment) at $102 million. SYFOVRE achieved 60% market share with 17% year-over-year injection growth, while EMPAVELI reached ...
The geographic atrophy market is expected to grow significantly due to rising global prevalence, aging populations, and emerging therapies targeting this advanced form of age-related macular degeneration.
Apellis Pharmaceuticals reported $459 million in Q3 2025 revenues, with $178 million from U.S. net product sales. The company highlighted new one-year data for EMPAVELI® demonstrating sustained efficacy in treating kidney diseases.
The complement 3 glomerulopathy market is projected to grow at a 37.2% CAGR from 2025-2034, driven by increasing disease awareness, advances in complement pathway research, and emerging targeted therapies targeting novel complement mechanisms.
